Notícias e Atividades da Journey Medical Corp

Journey Medical Corp pertence à Fortress Biotech.

Fortress Biotech é uma empresa listada sob o símbolo FBIO (US).

Fortress Biotech possui 4 subsidiárias incluindo Avenue Therapeutics, Checkpoint Therapeutics e Journey Medical Corp.

Eles estão dentro:

• Biotecnologia80%
• Farmacêutica20%

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Journey Medical Corp

• Claude Maraoui, Director, President and Chief Executive Officer
• Justin Smith, Director
• Michael Pearce, Director

Recentes movimentos de executivos em Journey Medical Corp

• Ramsey Alloush antes General Counsel, foi promovido a Chief Operating Officer and General Counsel  (Notícia publicada em 2 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da Journey Medical Corp.

Fortress Biotech possui 1.827 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Journey Medical Corp

• Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
• Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
• Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
• Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
• Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
• Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
• Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
• View more press releases Close

Redes sociais sobre Journey Medical Corp

• Journey Medical Corp na Wikipedia, Google News e Yahoo Finance
• Journey Medical Corp na LinkedIn, Twitter e YouTube